Judith Atz

428 total citations
24 papers, 343 citations indexed

About

Judith Atz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Judith Atz has authored 24 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Judith Atz's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cancer Genomics and Diagnostics (6 papers). Judith Atz is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cancer Genomics and Diagnostics (6 papers). Judith Atz collaborates with scholars based in Germany, United States and Austria. Judith Atz's co-authors include Olivier Gires, Karin Fellinger, Peter Ruf, Horst Lindhofer, Michael Jäger, William H. Schubach, Özlem Türeci, Nikolaus Mueller‐Lantzsch, Elisabeth Kremmer and Friedrich A. Grässer and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Judith Atz

24 papers receiving 333 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Judith Atz Germany 10 205 126 83 66 65 24 343
Natascha Rieder Switzerland 8 149 0.7× 97 0.8× 85 1.0× 50 0.8× 166 2.6× 17 359
Roger Grau Switzerland 6 167 0.8× 104 0.8× 66 0.8× 84 1.3× 45 0.7× 9 305
Giselle Saurez Cuba 8 203 1.0× 223 1.8× 172 2.1× 138 2.1× 80 1.2× 11 459
Eijiro Nagasaki Japan 12 183 0.9× 105 0.8× 147 1.8× 41 0.6× 35 0.5× 25 325
Massimiliano Dall’Ora Italy 10 213 1.0× 140 1.1× 89 1.1× 32 0.5× 44 0.7× 15 361
Liliana Ascione Italy 11 287 1.4× 88 0.7× 76 0.9× 145 2.2× 96 1.5× 25 396
L. Dirix Belgium 9 357 1.7× 120 1.0× 70 0.8× 93 1.4× 86 1.3× 15 483
Nicholas C.L. Wong Hong Kong 7 226 1.1× 171 1.4× 68 0.8× 164 2.5× 40 0.6× 10 398
Philippe De La Rochère France 6 206 1.0× 149 1.2× 202 2.4× 31 0.5× 40 0.6× 7 478
Alexandro Landshammer Germany 6 322 1.6× 122 1.0× 229 2.8× 42 0.6× 81 1.2× 8 476

Countries citing papers authored by Judith Atz

Since Specialization
Citations

This map shows the geographic impact of Judith Atz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Atz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Atz more than expected).

Fields of papers citing papers by Judith Atz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Atz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Atz. The network helps show where Judith Atz may publish in the future.

Co-authorship network of co-authors of Judith Atz

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Atz. A scholar is included among the top collaborators of Judith Atz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Atz. Judith Atz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Stephen V., Misako Nagasaka, Judith Atz, Flavio Solca, & Leonhard Müllauer. (2025). Oncogenic gene fusions in cancer: from biology to therapy. Signal Transduction and Targeted Therapy. 10(1). 111–111. 5 indexed citations
2.
3.
Grohé, Christian, Werner J. Blau, Wolfgang Gleiber, et al.. (2022). Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study. Clinical Oncology. 34(7). 459–468. 13 indexed citations
4.
Grohé, Christian, Thomas Wehler, Tobias Dechow, et al.. (2022). Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO. Translational Lung Cancer Research. 11(10). 2010–2021. 14 indexed citations
5.
Metzenmacher, Martin, Kato Kambartel, Jens Panse, et al.. (2021). Real-World Efficacy of Docetaxel Plus Nintedanib After Chemo-Immunotherapy Failure in Advanced Pulmonary Adenocarcinoma. Future Oncology. 17(30). 3965–3976. 7 indexed citations
6.
7.
8.
9.
Grohé, Christian, Wolfgang Blau, Wolfgang Gleiber, et al.. (2019). Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Preliminary efficacy and safety results of the non-interventional study VARGADO.. Journal of Clinical Oncology. 37(15_suppl). 9074–9074. 3 indexed citations
10.
Grohé, Christian, Werner J. Blau, Stefan Krüger, et al.. (2018). Nintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape. Annals of Oncology. 29. viii545–viii545. 2 indexed citations
11.
Atanackovic, Djordje, Henrike Reinhard, Sabrina Meyer, et al.. (2013). The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Human Vaccines & Immunotherapeutics. 9(12). 2533–2542. 22 indexed citations
12.
Lindemann, Carsten, et al.. (2012). Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo. Clinical & Translational Oncology. 14(5). 376–381. 10 indexed citations
13.
Lindemann, Carsten, et al.. (2011). Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clinical & Translational Oncology. 13(12). 889–898. 11 indexed citations
14.
15.
Atz, Judith, et al.. (2010). Abstract 3481: Establishment of preclinical models to identify clinically useful combinations of trifunctional antibodies with chemotherapy. Cancer Research. 70(8_Supplement). 3481–3481. 2 indexed citations
16.
Riechelmann, Herbert, Markus Wiesneth, Peter Schauwecker, et al.. (2007). Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunology Immunotherapy. 56(9). 1397–1406. 25 indexed citations
17.
Ruf, Peter, Olivier Gires, Michael Jäger, et al.. (2007). Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. British Journal of Cancer. 97(3). 315–321. 81 indexed citations
18.
Atz, Judith, et al.. (2000). Function, oligomerization, and conformation of tumor-associated p53 proteins with mutated C-terminus. Journal of Cellular Biochemistry. 76(4). 572–584. 19 indexed citations
19.
Grundhoff, Adam, Elisabeth Kremmer, Özlem Türeci, et al.. (1999). Characterization of DP103, a Novel DEAD Box Protein That Binds to the Epstein-Barr Virus Nuclear Proteins EBNA2 and EBNA3C. Journal of Biological Chemistry. 274(27). 19136–19144. 89 indexed citations
20.
Atz, Judith, et al.. (1997). A function in apoptosis other than transactivation inherent in the NH2-terminal domain of p53. International Journal of Cancer. 71(5). 858–866. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Natascha Rieder Breakdown of academic impact, for papers by Roger Grau Breakdown of academic impact, for papers by Giselle Saurez Breakdown of academic impact, for papers by Eijiro Nagasaki Breakdown of academic impact, for papers by Massimiliano Dall’Ora Breakdown of academic impact, for papers by Liliana Ascione Breakdown of academic impact, for papers by L. Dirix Breakdown of academic impact, for papers by Nicholas C.L. Wong Breakdown of academic impact, for papers by Philippe De La Rochère Breakdown of academic impact, for papers by Alexandro Landshammer
Rankless by CCL
2026